Research programme: infectious disease mRNA vaccines - Wuhan Rhecogen Biotechnology
Alternative Names: Research programme: infectious disease vaccines - Wuhan Rhecogen BiotechnologyLatest Information Update: 15 Dec 2021
At a glance
- Originator Wuhan Rhecogen Biotechnology
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections; Infections
Most Recent Events
- 29 Sep 2021 Jiangsu Recbio Technology and Shenzhen Rhegen Biotechnology signs a joint venture agreement to establish Wuhan Rhecogen Biotechnology for developing infectious disease vaccines
- 29 Sep 2021 Early research in COVID-2019 infections (Prevention) in China (Parenteral)
- 29 Sep 2021 Early research in Infections (Prevention) in China (Parenteral)